• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    11/2/22 8:20:19 AM ET
    $ACOR
    $ARCT
    $CLSD
    $CTSO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million.
    • Arcturus Therapeutics (NASDAQ:ARCT) shares moved upwards by 29.92% to $23.75. The company's market cap stands at $631.1 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 28.91% to $3.21. The market value of their outstanding shares is at $9.9 million.
    • CytoSorbents (NASDAQ:CTSO) stock increased by 12.16% to $2.12. The company's market cap stands at $92.3 million.
    • Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 10.74% to $1.34. The company's market cap stands at $80.6 million.
    • Edap TMS (NASDAQ:EDAP) stock moved upwards by 10.28% to $10.4. The market value of their outstanding shares is at $375.9 million.

    Losers

    • TFF Pharmaceuticals (NASDAQ:TFFP) stock decreased by 37.4% to $1.69 during Wednesday's pre-market session. The market value of their outstanding shares is at $43.0 million.
    • Ligand Pharmaceuticals (NASDAQ:LGND) shares declined by 23.18% to $65.0. The market value of their outstanding shares is at $1.0 billion.
    • PhaseBio Pharmaceuticals (NASDAQ:PHAS) shares fell 10.74% to $0.08. The company's market cap stands at $4.2 million.
    • Acorda Therapeutics (NASDAQ:ACOR) stock decreased by 10.02% to $0.72. The company's market cap stands at $17.5 million. The company's, Q3 earnings came out yesterday.
    • Sonnet BioTherapeutics (NASDAQ:SONN) shares fell 8.13% to $2.6. The company's market cap stands at $11.2 million.
    • Nutex Health (NASDAQ:NUTX) shares fell 7.46% to $0.75. The company's market cap stands at $487.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ARCT
    $CLSD
    $CTSO

    CompanyDatePrice TargetRatingAnalyst
    Ligand Pharmaceuticals Incorporated
    $LGND
    3/11/2026$244.00Buy
    BofA Securities
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    1/23/2026$20.00Buy
    Roth Capital
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Ligand Pharmaceuticals Incorporated
    $LGND
    12/9/2025$270.00Buy
    Citigroup
    Monopar Therapeutics Inc.
    $MNPR
    11/14/2025Strong Buy → Outperform
    Raymond James
    Monopar Therapeutics Inc.
    $MNPR
    11/10/2025$115.00Outperform
    Leerink Partners
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    10/24/2025$12.00Buy → Neutral
    H.C. Wainwright
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    10/23/2025$12.00Buy → Neutral
    Citigroup
    More analyst ratings

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference

    EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference Company to Present and Host 1x1 Investor Meetings on Wednesday, March 18th, 2026 AUSTIN, Texas, March 10, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Date: Wednesday, March 18th Time: 12:00-12:30 PM ET Format: Virtual Presentation and 1x1 investor meetings Webcast:https://event.summitcast.com/vi

    3/10/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    Arcturus Therapeutics to Attend Upcoming Investor Conference

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations/Events section of Arcturus' website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a messenger RNA medicines company focused on the development of liver a

    3/5/26 9:00:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Ligand Pharma with a new price target

    BofA Securities initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $244.00

    3/11/26 8:38:58 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

    Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00

    1/23/26 8:16:17 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    Chief Financial Officer Espinoza Octavio exercised 2,405 shares at a strike of $92.65 and sold $687,825 worth of shares (3,057 units at $225.00), decreasing direct ownership by 3% to 21,010 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    3/13/26 7:29:34 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Nutex Health Inc.

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/11/26 6:27:50 PM ET
    $NUTX
    Real Estate

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    SEC Filings

    View All

    SEC Form DEFA14A filed by Nutex Health Inc.

    DEFA14A - Nutex Health Inc. (0001479681) (Filer)

    3/13/26 4:02:10 PM ET
    $NUTX
    Real Estate

    SEC Form DEF 14A filed by Nutex Health Inc.

    DEF 14A - Nutex Health Inc. (0001479681) (Filer)

    3/13/26 4:01:49 PM ET
    $NUTX
    Real Estate

    SEC Form S-8 POS filed by Nutex Health Inc.

    S-8 POS - Nutex Health Inc. (0001479681) (Filer)

    3/12/26 4:32:12 PM ET
    $NUTX
    Real Estate

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    Financials

    Live finance-specific insights

    View All

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    PRINCETON, N.J., March 5, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year ended December 31, 2025, on Wednesday, March 25, 2026. CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents' flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada mar

    3/5/26 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026

    EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026 Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT AUSTIN, Texas, March 4, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before market open on Wednesday, March 25, 2026. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below f

    3/4/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    Leadership Updates

    Live Leadership Updates

    View All

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EDAP Announces Appointment of David Horn to Board of Directors

             EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (NASDAQ:EDAP) ("the Company" or "EDAP"), a global leader in therapeutic ultrasound technology, today announced the appointment of David Horn to its Board of Directors, effective February 11, 2026. The addition of Mr. Horn strengthens the Board with extensive experience both advising and leading companies through periods of strategic growth and transformation. Mr. Horn will serve as a member of the Company's Audit Committee and Nominations Committee. "We are pleased to welcome David to the EDAP Board," said Lance Willsey, Chairman of the Board of EDAP. "David brings dee

    2/12/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER

    HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments  in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Wesley Bamburg as the Company's Chief Operating Officer, effective October 13, 2025. Mr. Bamburg is an accomplished healthcare executive with 20 years of Fortune 500 experience in healthcare operations, business development, integrated network management, and physician relations. Mr. Bamburg has served as Chief Operating Officer for HCA Houst

    9/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ARCT
    $CLSD
    $CTSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc.

    SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

    11/19/24 4:05:58 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cytosorbents Corporation

    SC 13G/A - Cytosorbents Corp (0001175151) (Subject)

    11/14/24 4:48:32 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care